Millennium Pharmaceuticals and co-development partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) have initiated a three-arm, randomized, Phase II study of Velcade and pemetrexed in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed prior chemotherapy treatment. The study will assess the potential benefits of combining the activity of two targeted therapies with different mechanisms of action. Also underway is ...